Our experience with immune checkpoint inhibitors in triple-negative breast cancer patients

被引：0

作者：

Nishio, Minako ^{[1
]}

Kojitani, Yoshiki ^{[1
]}

Kitashiro, Saya ^{[1
]}

Ishiduka, Yasunobu ^{[1
]}

Otsuka, Tomoyuki ^{[1
]}

Nishida, Naohiro ^{[1
]}

Fujisawa, Fumie ^{[1
]}

Sugimoto, Naotoshi ^{[1
]}

Yagi, Toshinari ^{[1
]}

Souma, Ai ^{[2
]}

Kanaoka, Haruka ^{[2
]}

Oyamayama, Yuri ^{[2
]}

Taniguchi, Azusa ^{[2
]}

Nakajima, Satomi ^{[2
]}

Seto, Yukiko ^{[2
]}

Kusama, Hiroki ^{[2
]}

Watanabe, Noriyuki ^{[2
]}

Matsui, Saki ^{[2
]}

Nakayama, Takahiro ^{[2
]}

Kudou, Toshihiro ^{[1
]}

机构：

[1] Osaka Int Canc Inst, Osaka Prefectural Hosp Org, Dept Med Oncol, Osaka, Japan

[2] Osaka Int Canc Inst, Osaka Prefectural Hosp Org, Dept Breast Surg, Osaka, Japan

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.3098

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P67-5

引用

页码：S1465 / S1465

页数：1

共 50 条

[21] HDAC inhibition modulates immune checkpoint pathway in triple-negative breast cancer
Barberio, Manuela Terranova
Thomas, Scott
Ali, Niwa
Pawlowska, Nela
Park, Jeenah
Rosenblum, Michael D.
Budillon, Alfredo
Munster, Pamela N.
CANCER IMMUNOLOGY RESEARCH, 2018, 6 (09)
[22] Preclinical Platform Using a Triple-negative Breast Cancer Syngeneic Murine Model to Evaluate Immune Checkpoint Inhibitors
Katuwal, Nar Bahadur
Park, Nahee
Pandey, Kamal
Kang, Min Sil
Hong, Sa Deok
Ghosh, Mithun
Kim, Seul-Gi
Cho, Young Bin
Hur, Jin
Kim, Seung Ki
Moon, Yong Wha
ANTICANCER RESEARCH, 2023, 43 (01) : 85 - 95
[23] Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges
Uchimiak, Katarzyna
Badowska-Kozakiewicz, Anna M.
Sobiborowicz-Sadowska, Aleksandra
Deptala, Andrzej
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
[24] Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges
Uchimiak, Katarzyna
Badowska-Kozakiewicz, Anna M.
Sobiborowicz-Sadowska, Aleksandra
Deptala, Andrzej
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2022, 16
[25] Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker
Qureshi, Sadaf
Chan, Nancy
George, Mridula
Ganesan, Shridar
Toppmeyer, Deborah
Omene, Coral
BIOMARKER INSIGHTS, 2022, 17
[26] Checkpoint Inhibitors in Triple-Negative Breast Cancer (TNBC): Where to Go From Here
Kwa, Maryann J.
Adams, Sylvia
CANCER, 2018, 124 (10) : 2086 - 2103
[27] Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors
Vici, Patrizia
Pizzuti, Laura
Krasniqi, Eriseld
Botticelli, Andrea
Ciliberto, Gennaro
Barba, Maddalena
IMMUNOTHERAPY, 2020, 12 (10) : 675 - 679
[28] Immune checkpoint inhibitors addition to chemotherapy in older patients with metastatic triple-negative breast cancer: A systematic review and meta-analysis
Pagliuca, M.
Bencivenga, L.
Komici, K.
De Angelis, C.
Caputo, R.
Napolitano, F.
Cianniello, D.
Di Lauro, V.
Rengo, G.
De Placido, S.
Andre, F.
De laurentiis, M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S655 - S655
[29] Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer
Camorani, Simona
Passariello, Margherita
Agnello, Lisa
Esposito, Silvia
Collina, Francesca
Cantile, Monica
Di Bonito, Maurizio
Ulasov, Ilya V.
Fedele, Monica
Zannetti, Antonella
De Lorenzo, Claudia
Cerchia, Laura
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
[30] Inhibition of Notch enhances efficacy of immune checkpoint blockade in triple-negative breast cancer
Shen, Qiang
Murakami, Kiichi
Sotov, Valentin
Butler, Marcus
Ohashi, Pamela S.
Reedijk, Michael
SCIENCE ADVANCES, 2024, 10 (44):

← 1 2 3 4 5 →